These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20572051)

  • 1. Subtilisin-γ-glutamyl transpeptidase: a novel combination as ungual enhancer for prospective topical application.
    Tiwary E; Gupta R
    J Pharm Sci; 2010 Dec; 99(12):4866-73. PubMed ID: 20572051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An investigation into keratinolytic enzymes to enhance ungual drug delivery.
    Mohorcic M; Torkar A; Friedrich J; Kristl J; Murdan S
    Int J Pharm; 2007 Mar; 332(1-2):196-201. PubMed ID: 17097244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved catalytic efficiency of a monomeric gamma-glutamyl transpeptidase from Bacillus licheniformis in presence of subtilisin.
    Tiwary E; Gupta R
    Biotechnol Lett; 2010 Aug; 32(8):1137-41. PubMed ID: 20401515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of ciclopirox nail lacquer with enhanced permeation and retention.
    Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
    Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers.
    Khengar RH; Jones SA; Turner RB; Forbes B; Brown MB
    Pharm Res; 2007 Dec; 24(12):2207-12. PubMed ID: 17665289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing the nail permeability of topically applied drugs.
    Murdan S
    Expert Opin Drug Deliv; 2008 Nov; 5(11):1267-82. PubMed ID: 18976136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
    Elsayed MM
    J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy.
    Mertin D; Lippold BC
    J Pharm Pharmacol; 1997 Sep; 49(9):866-72. PubMed ID: 9306253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ungual and transungual drug delivery.
    Shivakumar HN; Juluri A; Desai BG; Murthy SN
    Drug Dev Ind Pharm; 2012 Aug; 38(8):901-11. PubMed ID: 22149347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro permeation and penetration of ciclopirox olamine from poloxamer 407-based formulations--comparison of isolated human stratum corneum, bovine hoof plates and keratin films.
    Täuber A; Müller-Goymann CC
    Int J Pharm; 2015 Jul; 489(1-2):73-82. PubMed ID: 25895717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery to the nail following topical application.
    Murdan S
    Int J Pharm; 2002 Apr; 236(1-2):1-26. PubMed ID: 11891066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TranScreen-N: Method for rapid screening of trans-ungual drug delivery enhancers.
    Murthy SN; Vaka SR; Sammeta SM; Nair AB
    J Pharm Sci; 2009 Nov; 98(11):4264-71. PubMed ID: 19363796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Tampucci S; Mailland F
    Br J Dermatol; 2011 Jul; 165(1):99-105. PubMed ID: 21410668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Hansen Solubility Parameters to predict drug-nail interactions, which can assist the design of nail medicines.
    Hossin B; Rizi K; Murdan S
    Eur J Pharm Biopharm; 2016 May; 102():32-40. PubMed ID: 26924329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: penetration of chloramphenicol from lipophilic vehicles and a nail lacquer.
    Mertin D; Lippold BC
    J Pharm Pharmacol; 1997 Mar; 49(3):241-5. PubMed ID: 9231338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transungual drug delivery: current status.
    Elkeeb R; AliKhan A; Elkeeb L; Hui X; Maibach HI
    Int J Pharm; 2010 Jan; 384(1-2):1-8. PubMed ID: 19819318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
    Traynor MJ; Turner RB; Evans CR; Khengar RH; Jones SA; Brown MB
    J Pharm Pharmacol; 2010 Jun; 62(6):730-7. PubMed ID: 20636860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of the diffusional barrier property of the nail leads to greater terbinafine drug loading and permeation.
    Nair AB; Sammeta SM; Kim HD; Chakraborty B; Friden PM; Murthy SN
    Int J Pharm; 2009 Jun; 375(1-2):22-7. PubMed ID: 19481686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of polyethylene glycols on the trans-ungual delivery of terbinafine.
    Nair AB; Chakraborty B; Murthy SN
    Curr Drug Deliv; 2010 Dec; 7(5):407-14. PubMed ID: 20955143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.
    Vejnovic I; Huonder C; Betz G
    Int J Pharm; 2010 Sep; 397(1-2):67-76. PubMed ID: 20620203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.